Scarica l'app Stockscreener
2.02
4.74%
0.12
Precedente Chiudi:
$1.90
Aprire:
$2
Volume 24 ore:
16,243
Relative Volume:
45.43
Capitalizzazione di mercato:
$N/A
Reddito:
$257.55M
Utile/perdita netta:
$11.95M
Rapporto P/E:
2.2198
EPS:
0.91
Flusso di cassa netto:
$-9.39M
1 W Prestazione:
+4.74%
1M Prestazione:
-76.15%
6M Prestazione:
-81.21%
1 anno Prestazione:
-93.26%
Intervallo 1D:
$1.90
$2.175
Intervallo di 1 settimana:
$1.90
$2.175
Portata 52W:
$1.55
$2.175
Eagle Pharmaceuticals Inc Stock (EGRX) Company Profile
Confronta EGRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EGRX
Eagle Pharmaceuticals Inc
|
2.05 | 0 | 257.55M | 11.95M | -9.39M | 0.91 |
|
HLN
Haleon Plc Adr
|
10.96 | 50.54B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
169.94 | 74.02B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.85 | 4.12M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.05 | 45.57B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.31 | 20.31B | 16.54B | -1.64B | 749.00M | -1.45 |
Eagle Pharmaceuticals Inc Stock (EGRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2018-11-01 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2018-10-31 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2018-03-21 | Reiterato | Mizuho | Underperform |
| 2017-11-09 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-06 | Reiterato | Mizuho | Underperform |
| 2017-07-27 | Reiterato | Mizuho | Underperform |
| 2017-07-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-05-09 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-01-09 | Downgrade | Mizuho | Neutral → Underperform |
| 2016-11-16 | Downgrade | Mizuho | Buy → Neutral |
| 2016-11-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2016-11-03 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-26 | Reiterato | Mizuho | Buy |
| 2016-08-16 | Reiterato | Mizuho | Neutral |
| 2016-06-20 | Downgrade | Mizuho | Buy → Neutral |
| 2016-05-10 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-03-18 | Reiterato | Mizuho | Buy |
| 2016-02-26 | Reiterato | Mizuho | Buy |
| 2015-12-09 | Iniziato | Mizuho | Buy |
| 2015-07-29 | Reiterato | Piper Jaffray | Overweight |
Mostra tutto
Eagle Pharmaceuticals Inc Borsa (EGRX) Ultime notizie
EGRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm! - ACCESS Newswire
SHAREHOLDER ALERT: Potential Recovery for Eagle Pharmaceuticals, Inc. (EGRX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
EGRX STOCKHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Eagle Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
EGRX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Eagle Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - Eagle-Tribune
Heparin-Induced Thrombocytopenia (HIT) Market: A Serious Drug Reaction Explained 2025-2033 - openPR.com
Bacterial Pneumonia Market: How to Identify and Treat This Serious Lung Infection - openPR.com
ATNM DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. ... - Eagle-Tribune
D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) in connection with its $13.5 Million Initial Public Offering - Eagle-Tribune
Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com - Defense World
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - Eagle-Tribune
Shareholders that lost money on Eagle Pharmaceuticals, Inc. (EGRX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors of a ... - Eagle-Tribune
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.com - Defense World
Bacterial Pneumonia Therapeutics Market 2032: Clinical - openPR.com
INVESTOR ALERT: Potential Recovery for Eagle Pharmaceuticals, Inc. (EGRX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc. (EGRX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc.(EGRX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc. (EGRX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Seeking Recovery for Investors ... - Eagle-Tribune
Press Release Distribution & PR Platform - ACCESS Newswire
Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com - The AM Reporter
EmpiRx Health Partners with Giant Eagle to Transform Pharmacy Benefits Care - PR Newswire
Eagle Pharmaceuticals Shares Turn Positive After Positive 2022 Outlook - marketscreener.com
Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender AgreementHagens Berman - ACCESS Newswire
Latham Watkins Advises Eagle Pharmaceuticals in Royalty Monetization With Blue Owl Capital - Latham & Watkins LLP
Eagle Pharmaceuticals Announces $69 Mln Agreement To Monetize Bendeka Royalties - marketscreener.com
Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties - The Manila Times
Major Cash Injection: Eagle Pharma Lands $69M Through Strategic Royalty Sale - Stock Titan
StockNews.com Initiates Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX) - Defense World
Eagle Pharmaceuticals (NASDAQ:EGRX) Share Price Crosses Below 200-Day Moving Average – Here’s Why - Defense World
Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan - The Manila Times
Eagle Pharmaceuticals announces amendment to limited duration stockholder rights plan - Marketscreener.com
Eagle Pharmaceuticals Doubles Anti-Takeover Protection to $20 in Rights Plan Update - Stock Titan
Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Crosses Below Two Hundred Day Moving Average – Here’s Why - Defense World
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com - Defense World
Eagle Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by IFP Advisors Inc - Defense World
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Eagle Pharmaceuticals, Inc. (EGRX) - ACCESS Newswire
SHAREHOLDER ALERT: Potential Recovery for Eagle Pharmaceuticals, Inc. (EGRX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
EGRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Eagle Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Class Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX)February 9, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX) - Defense World
Revelation Pharma Appoints Nancy Fingerhut as Vice President of Quality Assurance and Regulatory Affairs - PR Newswire
Eagle Pharmaceuticals Inc Azioni (EGRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.23%
0.54%
Capitalizzazione:
|
Volume (24 ore):